Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Expert Opinion / Cases · May 03, 2017

Widely Metastatic ccRCC in 40-Year-Old Female

Written by
Heather R Greene MSN, FNP, AOCNP


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • rebaz haji

    Nov 24, 2017

    use temsirolimus because poor risk category 

  • Huan Wang

    Jan 29, 2018

    Considering type of histology is ccRCC. So I believe sunitinib or pazopanib is first-line treatment choice for the patient.

  • Dec 07, 2023

    Pending Moderator approval.

Further Reading